The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.
 
Emma Hyddmark
No Relationships to Disclose
 
Donald Berry
Employment - Berry Consultants
Leadership - Berry Consultants
Stock and Other Ownership Interests - Berry Consultants
Consulting or Advisory Role - Berry Consultants
Travel, Accommodations, Expenses - Berry Consultants
 
Nicholas Berry
No Relationships to Disclose
 
Howard Colman
Consulting or Advisory Role - Alpha Biopharma; Best Doctors, Inc; Chimerix; Novartis; Orbus Therapeutics; PPD; SERVIER; Sumitomo Pharma Oncology
Research Funding - Anheart Therapeutics (Inst); Bayer (Inst); CNS Pharmaceuticals; Erasca, Inc (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Samus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Other Relationship - Chimerix/PPD
 
John de Groot
Consulting or Advisory Role - Alpha Pharmaceutical; CapitalOne; CarThera; Deciphera; DSP Pharma; InSightech; Kazia Therapeutics; Kintara Therapeutics; Monteris Medical; MündiPharma; Nerviano Medical Sciences; Nerviano Medical Sciences; Samus; Samus; Sapience Therapeutics; SERVIER; Telix Pharmaceuticals
Other Relationship - Chimerix; VBI Vaccines
 
Benjamin Ellingson
Consulting or Advisory Role - Alpheus Medical; CarThera; Chimerix; Curtana; Ellipses Pharma; Global Coalition for Adaptive Research; Imaging Endpoints; ImmunoGenesis; Medicenna; Monteris Medical; Neosoma; Orbus Therapeutics; Sagimet Biosciences; Sapience Therapeutics; SERVIER; Siemens; Sumitomo Dainippon Pharma Oncology; Voiant/MedQIA
Research Funding - Siemens
Travel, Accommodations, Expenses - Siemens
 
Hui Gan
Consulting or Advisory Role - Curis Pharmaceuticals; Curis Pharmaceuticals; Grey Wolf; Merck KGaA; MSD; Servier; Servier; Telix Pharmaceuticals
Speakers' Bureau - Daichii Sankyo
Research Funding - AbbVie
 
Adam Johnson
No Relationships to Disclose
 
Andrew Lassman
Consulting or Advisory Role - Alpha Detail; Bluestar Bioadvisors; Curio Science; Fore Biotherapeutics; Gerson Lehrman Group; Global Coalition for Adaptive Research; Guidepoint Global; Modifi Bio; Orbus Therapeutics; Reach Market Research; Sapience Therapeutics; Servier
Research Funding - Abbott Laboratories (Inst); Abbvie (Inst); Aeterna Zentaris (Inst); AstraZeneca (Inst); Bayer (Inst); Biohaven Pharmaceuticals (Inst); BMS (Inst); Chimerix (Inst); Corden (Inst); DelMar Pharmaceuticals (Inst); Genentech/Roche (Inst); Global Coalition for Adaptive Research (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Kazia Therapeutics (Inst); Kintara Therapeutics (Inst); NextSource (Inst); Novartis (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); Polaris (Inst); QED Therapeutics (Inst); Servier (Inst); VBI Vaccines (Inst); Vigeo Therapeutics (Inst)
Travel, Accommodations, Expenses - Abbvie; Anheart Therapeutics; Foundation Medicine; Gilead Sciences; Global Coalition for Adaptive Research; Incyte; Modifi Bio; Moving Innovation and Technology; Orbus Therapeutics; Sapience Therapeutics; Servier; VBI Vaccines
 
Michael Lim
Stock and Other Ownership Interests - Egret Bioscience
Honoraria - Accuray; Agenus; Bristol-Myers Squibb; InSightec; Merck; Oncorus; Stryker; tocagen
Consulting or Advisory Role - Biohaven Pharmaceuticals; Bristol-Myers Squibb; CraniUs; Egret Bioscience; Global Coalition for Adaptive Research; Hemispherian; Hoth Therapeutics; InCephalo Therapeutics/University of Zurich; Insightec; Mediflix; novocure; Noxxon Pharma; Pyramid Biosciences; Sanianoia; SERVIER; Stryker; VBI Vaccines
Research Funding - Accuray (Inst); Arbor Pharmaceuticals (Inst); Biohaven Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Combination of Immunotherapy with Local Chemotherapy for the Treatment of Malignancies. (Inst); CXCR6 as an Immuno-oncology Target to Improve T cell Metabolic Response (Inst); Meteorin-like (METRNL) as an Immuno-oncology Target (Inst); Methods of Treating Myocardial Infarction, Ischemia, and Ischemia Reperfusion Injury (Inst); Methods Patent for Combining Immunotherapy with Radiation (Inst); Modulation of Oxidative Stress as a Therapeutic Pathway in Trigeminal Neuralgia (Inst); Novel Immunotherapeutic Targets Identified in Patients with Glioblastoma using RNA Sequencing to Compare Gene Expression Patterns in Tumor Infiltrating (TIL) and Peripheral Blood Lymphocytes (Inst); Polyfunctional lymphocytes as a biomarker of antitumor activity (Inst); Post-surgical imaging marker: A marker for imaging includes a bio-dissolvable material and a contrast agent configured to provide contrast during an imaging procedure. (Inst); Program Death 1 (PD-1) Agonists for the Treatment of Cerebral Vasospasm (Inst); Sustained and Localized Antibody and Immunotherapeutic Delivery to Lymph Nodes (Inst); Universal Microport (Inst); Use of Anti-PD-1 Delivery with the Urogen® Polymer to Tumor Draining Lymph Nodes for Treatment of Cancers (Inst); Use of the ZMIZ1 Marker in Directing Treatment and Predicting Survival in Cancer. (Inst)
Travel, Accommodations, Expenses - Accuray; SERVIER; Stryker
 
Ingo Mellinghoff
Consulting or Advisory Role - Black Diamond Therapeutics; Pathos; Prelude Therapeutics; Roche; Tango Therapeutics
Speakers' Bureau - SERVIER
Travel, Accommodations, Expenses - SERVIER
 
James Perry
Leadership - Global Coalition for Adaptive Research
Stock and Other Ownership Interests - Synaptive medical
Honoraria - Novocure; SERVIER
Consulting or Advisory Role - Servier Canada
Travel, Accommodations, Expenses - Servier MSP
 
Erik Sulman
Honoraria - Baptist Health South Florida; BrainLAB; Peerview
Consulting or Advisory Role - Global Coalition for Adaptive Research; Harvard Medical School; Telix Pharmaceuticals
Research Funding - Novocure (Inst)
Patents, Royalties, Other Intellectual Property - CARPOOL pooled cell line drug screening
Travel, Accommodations, Expenses - Baptist Health South Florida; BrainLAB; Peerview
 
Michael Weller
Honoraria - Bayer; Novocure
Consulting or Advisory Role - AstraZeneca (I); Bayer (I); Biodexa (I); Curevac; Janssen (I); LEO Pharma (I); Medac; Medac (I); Novartis; Novartis; Novartis (I); Orbus Therapeutics; Pfizer (I); Philogen; Roche (I); Sandoz; Seagen (I); Seagen (I); Servier; Servier (I)
Research Funding - BMS (Inst); Novartis (Inst); Quercegen Pharmaceuticals (Inst); Versameb (Inst)
 
Patrick Wen
Consulting or Advisory Role - Alexion Pharmaceuticals; Anheart Therapeutics; AstraZeneca; Bayer; Black Diamond Therapeutics; Bristol Myers Squibb Foundation; Celularity; Chimerix; Day One Biopharmaceuticals; Fore Biotherapeutics; Genenta Science; GlaxoSmithKline; Kintara Therapeutics; Merck; Mundipharma; Mundipharma; Novocure; Novocure; Nuvation Bio; Sapience Therapeutics; Servier; Servier; SymBio Pharmaceuticals; Tango Therapeutics; Telix Pharmaceuticals
Research Funding - AstraZeneca (Inst); Bayer (Inst); Black Damond (Inst); Bristol-Myers Squibb/Medarex (Inst); Chimerix (Inst); Erasca, Inc (Inst); Erasca, Inc (Inst); Global Coalition for Adaptive Research (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Philogen (Inst); Quadriga Biosciences (Inst); Servier (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)
 
Timothy Cloughesy
Leadership - Katmai Pharmaceuticals
Stock and Other Ownership Interests - Chimerix; Erasca, Inc; Katmai Pharmaceuticals
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Chimerix; DelMar Pharmaceuticals; Global Coalition for Adaptive Research; Inovio Pharmaceuticals; Katmai Pharmaceuticals; KIYATEC; Lista; Merck; Mundipharma; Novartis; QED Therapeutics; Roche/Genentech; Sapience Therapeutics; SERVIER; SonaCare Medical; SymBio Pharmaceuticals; Tango Therapeutics; Tocagen; VBL Therapeutics
Patents, Royalties, Other Intellectual Property - U.S. Provisional Application No.: 62/819,322 Title: COMPOSITIONS AND METHODS FOR TREATING CANCER Filing Date: March 15, 2019 Inventor(s): David A. Nathanson et al. FH Reference No.: UCH-17760 (32246-17760) Your Reference No.: [UCLA 2019-630-1] US
Other Relationship - Break Through Cancer; Global Coalition for Adaptive Research
 
GBM AGILE Trial Network
No Relationships to Disclose